 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Wuxi PharmaTech (WX) operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States.
It operates in two segments, Laboratory Services and Manufacturing Services.
The Laboratory Services segment offers services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, and research reagent production, as well as services for discovery and development of biologics; and testing services for biologics, medical devices, and combination products.
The Manufacturing Services segment engages in the production of manufacturing advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and for commercial products, as well as the production of biologics.
The company sells its products directly to pharmaceutical, biotechnology, and medical device companies. Shares have formed a "double bottom" and higher share prices are expected for this stock.
52-Week Trading Range: $16.22 - $40.72
Entry Point: $35.86
Stop Loss: $34.07
Target Price: $39.45
WX closed with a modest gain at $36.75.
